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ABSTRACT
Objective: To investigate the association between initial
quetiapine dose and effectiveness as gauged by subse-
quent use of mental health services.
Methods: Using a health plan database, we identiﬁed
patients with bipolar disorder or schizophrenia treated
with quetiapine monotherapy for at least four consecutive
months. The stability of each patient before and after
quetiapine treatment was measured by use of mental
health services other than antipsychotic drug, measured
primarily by charges reported on claims. Regression mod-
els controlling for patient differences measured associa-
tions between initial quetiapine dose and subsequent
mental health service use.
Results: Commercially insured patients with schizophre-
nia (n = 581) or bipolar disorder (n = 2421) received
quetiapine monotherapy at mean (SD) initial daily doses
of 237 (198) mg and 147 (171) mg, respectively. Both
groups showed negative associations between initial daily
dose and subsequent mental health charges. Among
patients with schizophrenia, mental health charges
decreased by $1.28 for each additional milligram of
quetiapine (P = 0.1097). Among patients with bipolar
disorder, there was a signiﬁcant decrease of $1.31 per
additional milligram of quetiapine (P = 0.0484). For
schizophrenia, hospitalizations were reduced by 0.4%
for each additional milligram of quetiapine (P = 0.0189).
For bipolar disorder, the association between quetiapine
dose and outpatient charges was negative and trended
toward signiﬁcance (P = 0.074), showing a $0.54 reduc-
tion in these charges for each additional milligram of
quetiapine; the association with hospitalization was not
signiﬁcant.
Conclusions: In patients with schizophrenia or bipolar
disorder, higher initial doses of quetiapine may be more
effective in stabilizing patients as reﬂected in lower sub-
sequent mental health service use.
Keywords: bipolar disorder, dosing, quetiapine, resource
use, schizophrenia.
Introduction
Quetiapine, a dibenzothiazepine, has been ap-
proved by the US Food and Drug Administration
for the treatment of schizophrenia and bipolar dis-
order. Its psychotropic effects are achieved through
antagonism at multiple neurotransmitter receptors,
including dopamine D2. Quetiapine’s low to moder-
ate afﬁnity for the D2 receptor and subsequent tran-
sient occupancy explains its low likelihood of
producing extrapyramidal symptoms [1]. Recom-
mended dosing for quetiapine in the treatment of
schizophrenia historically has been titration to
400 mg/day by day 5 and subsequent adjustment
to a maintenance dose of 150- to 750 mg/day in
patients who respond [1–5].
These relatively broad dosing recommendations
may in practice have resulted in many physicians
being too conservative in their quetiapine initiation
schedules [6]. At the time of this study, there were
no speciﬁc recommendations for bipolar disorder,
and it is assumed that quetiapine dosing practices
for this condition were inﬂuenced by the schizo-
phrenia guidelines.
Data suggest that D2-receptor occupancy medi-
ates the psychotropic effect and that, because of its
low to moderate afﬁnity, adequate occupancy of D2
receptors with quetiapine does not occur with doses
less than 400 mg/day [7–9]. One trial comparing
chronic or subchronic schizophrenia patients
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treated with low-dose or high-dose quetiapine
found that higher doses (in excess of 250 mg/day)
might be more effective than lower doses (150–
250 mg/day), particularly with respect to positive
symptoms [10]. Other ﬁndings suggest that quetia-
pine dose should be set even higher, 600 mg/day, to
achieve signiﬁcant improvement in cognitive func-
tion among schizophrenia patients [11]. Still higher
quetiapine doses may be appropriate for schizo-
phrenia patients who are treatment resistant. In a
trial involving seven treatment-refractory schizo-
phrenia inpatients who were given 1200- to
2400 mg/day of quetiapine over a 5- to 14-month
period, all experienced mild to marked improve-
ment in psychopathology, sociability, and other ill-
ness-related characteristics [12].
Quetiapine doses that are too low may not main-
tain remission of psychotic symptoms. This study
investigated the association between initial quetiap-
ine dose and effectiveness as reﬂected in subsequent
mental health service use by patients with schizo-
phrenia or bipolar disorder.
Methods
A claims-data extract from the PharMetrics
patient-centric database was used for this study
[13]. Patients with schizophrenia (ICD-9-CM codes
295.xx) or bipolar disorder (ICD-9-CM codes
296.4–296.8) who initiated an episode of quetia-
pine monotherapy in 1999 to 2002 and who were
treated for at least four consecutive months were
identiﬁed. Some patients may have had earlier
treatment episodes with quetiapine predating the
data. Four months of treatment were selected
because it provided a reasonable amount of time
over which to gauge the effects of initial quetiapine
dose and because a longer period would have
resulted in considerable loss of sample as a result of
discontinuance of quetiapine or data truncation.
Initial dose effectiveness was proxied by each
patient’s subsequent mental health service use.
Mental health charges exclusive of quetiapine
charges served as the comprehensive measure of
mental health service use. The purpose of antipsy-
chotic therapy is to stabilize the patient; therefore,
inclusion of antipsychotic drug charges as a compo-
nent of mental health charges is incompatible with
the use of this measure as a proxy for patient sta-
bility. Mental health charges consisted of those
appearing on all medical claims reporting a mental
disorder (ICD-9-CM codes 290.xx-316.xx) as the
primary diagnosis and on all prescription claims for
adjunctive psychotropic medications (antidepres-
sants, mood stabilizers, anxiolytics, hypnotics, and
anticholinergics).
Each patient’s ﬁrst quetiapine prescription within
the treatment episode was used to identify the target
daily dose. Initial daily dose was calculated from the
National Drug Code (NDC) (tablet strength), quan-
tity, and days supply reported  on  the  prescription
claim.  Nearly  95% of initial prescriptions were of
15 days’ supply or more, with 76% being for
30 days. Effects of quetiapine dose were measured
over months 2–4 of treatment. The ﬁrst month of
treatment was contemporaneous with the initial
dose and was considered to be a transition period
largely reﬂecting preexisting symptoms.
The mental health service use of each patient was
measured during the 3 months before the initiation
of quetiapine as well as during months 2–4 of treat-
ment. Prior mental health charges, exclusive of any
antipsychotic drug charges, reﬂect the stability of
each patient at the time that quetiapine therapy was
initiated. Prior charges also serve as a baseline for
comparing effects of differing initial dose levels on
subsequent charges.
Quetiapine monotherapy was assumed if there
were no prescriptions for another antipsychotic
ﬁlled during the 4-month period from the date of
the ﬁrst quetiapine prescription. We feel that this
was sufﬁcient to establish that there was no intent
to prescribe antipsychotic polypharmacy. The prior
3-month window was used to identify patients who
switched to quetiapine from another antipsychotic.
With claims data it is impossible to know the extent
to which prior prescriptions for other antipsychot-
ics, particularly those occurring nearer to the
quetiapine start date, were used during initial
quetiapine treatment. Guidelines for transitioning
from another antipsychotic to quetiapine are laid
out in Cutler et al. [5] and are more generally dis-
cussed in other publications [14,15]. Of the three
switching strategies outlined, only “cross tapering”
may result in a lower initial quetiapine dose as
reﬂected in the ﬁrst prescription claim. The data,
however, do not show that initial quetiapine doses
were lower for patients who switched from other
antipsychotics.
The association between initial quetiapine dose
and subsequent mental health service use was esti-
mated using ordinary least squares regression for
total and outpatient mental health charges and with
logistic regression for hospitalization. Logistic
regression was also used to estimate the effect of ini-
tial dose on odds of subsequently increasing dose.
The rationale here is that if initial quetiapine doses
are too conservative, the odds of subsequently
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increasing dose will be greater the lower the initial
dose. With initial dosing that is devoid of down-
ward or upward bias and that is based solely on
patient needs, there should be no statistical relation-
ship. Regression models controlled for patient age
and sex, type of schizophrenia or bipolar disorder,
switching from another antipsychotic, other health
charges during treatment (proxy for general health
status), type of health coverage, geographic loca-
tion, and stability at time of quetiapine initiation
gauged by prior mental health charges and the prior
number of different psychotropic medications used.
The central argument of this study is that a ten-
dency in practice to be too conservative with initial
quetiapine doses will be revealed in signiﬁcant neg-
ative associations between dose levels and subse-
quent levels of mental health service use. Signiﬁcant
statistical associations in either direction would not
be expected if physicians were more balanced in
their quetiapine initiation schedules. Although this
study used the P < 0.05 convention to categorize
estimates as statistically signiﬁcant, it is unrealistic
to discount estimates with P values that are near
this threshold. Such estimates may be clinically
relevant and are categorized as “trending toward
signiﬁcance.”
Results
Five hundred and eighty-one schizophrenia patients
and 2421 bipolar patients were treated with
quetiapine monotherapy for at least four consecu-
tive months between 1999 and 2002. Schizophrenia
patients had a mean (SD) initial dose of 237 (198)
mg/day and a median dose of 200 mg/day. About
one-third of these patients had doses below 150 mg/
day, the lower bound of the recommended range.
This suggests that many practitioners did not follow
the guidelines, as outlined in the Physicians Desk
Reference and other published sources [1–5] and
were conservative in their approach to initial
quetiapine dosing. Bipolar patients had an initial
mean (SD) dose of 147 (171) mg/day and median
dose of 100 mg/day, both of which are below
150 mg/day. In all, nearly two-thirds of bipolar
patients had initial doses below this lower bound.
The maximum observed dose was 1200 mg/day for
both diagnostic groups.
In Table 1, each diagnostic group was divided
into lower- and higher-dose cohorts, where lower
dose was deﬁned as less than or equal to the mean
and higher dose as above the mean. Among both
schizophrenia and bipolar patients, those initiated
on higher doses of quetiapine had considerably
larger prior mental health charges in comparison to
those initiated on lower doses. This suggests that
patients given higher initial doses were generally
less stable than those given lower doses.
For all groups, mental health charges in months
2–4 of quetiapine treatment were much lower than
those before initiation of treatment. These de-
creases, however, may be explained by a natural
“gravitation to the mean,” as well as by the thera-
peutic effects of quetiapine. Among schizophrenia
patients, those initiated on higher doses of quetiap-
ine had lower subsequent mental health charges
than those initiated on lower doses, whereas, the
opposite was true for bipolar patients. Regardless,
the higher-dose cohorts within each diagnostic
group had larger percent reductions in mental
health charges than the lower-dose cohorts. This is
a better indicator of relative effectiveness because of
the different needs of patients in the higher- and
lower-dose cohorts. Nevertheless, differences in
percent reductions may also reﬂect more intense
gravitation to the mean for the higher-dose versus
Table 1 Mental health service use of schizophrenia and bipolar patients by lower and higher quetiapine dose cohort*
Schizophrenia Bipolar 
Higher dose Lower dose Higher dose Lower dose
Number of patients 241 340 823 1598
Mean mental health charges during 3 months before treatment ($)† 7294 2885 5637 3545
Mean mental health charges during months 2–4 of treatment ($)† 1170 1463 1973 1683
Percent change in mental health charges (%) -84 -48 -64 -53
Mean hospital charges per patient in months 2–4 of treatment ($) 215 643 955 643
Percent of patients hospitalized in months 2–4 (%) 2.5 5.3 6.8 5.6
Mean outpatient charges per patient in months 2–4 of treatment ($) 797 645 795 815
Mean charges for adjunctive psychotropic medications per patient in 
months 2–4 of treatment ($)
158 175 223 225
*Higher dose is deﬁned as greater than or equal to and lower dose as less than the overall mean dose of 237 mg/day for schizophrenia and 147 mg/day for bipolar
disorder.
†Excludes antipsychotic drug charges.
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the lower-dose cohorts. The breakdown of mental
health charges indicates that, within each diagnostic
group, differences in mental health charges between
lower- and higher-dose cohorts are mostly ex-
plained by differences in hospitalization.
Although the higher-dose cohorts among both the
schizophrenia and bipolar groups had higher prior
mental health charges than the lower-dose cohorts,
a closer examination of the data showed that this
relationship was generally weak. Schizophrenia and
bipolar patients were stratiﬁed by prior charge
deciles, and mean charges for each decile were com-
pared with the mean initial quetiapine dose for each
decile. A visual assessment of the data revealed the
absence of an increasing relationship except in the
highest deciles. This ﬁnding suggests that initial
quetiapine doses were little governed by patient
symptomology except for the most severely ill.
Characteristics of schizophrenia and bipolar
patients stratiﬁed by lower- and higher-dose cohorts
are shown in Table 2. For both diagnostic groups,
there is large variation in initial quetiapine dose as
exempliﬁed by differences between the mean doses
for the lower- and higher-dose cohorts. Although
schizophrenia patients were older than bipolar
patients, quetiapine dose appears to be unrelated
to age. In both diagnostic groups, men were more
likely to be prescribed higher initial doses than
women, likely reﬂecting differences in body weight.
Among schizophrenia patients, those with the par-
anoid type were more likely to be prescribed higher
doses of quetiapine than those with schizoaffective
disorder and other schizophrenia types. Differences
among bipolar types were less pronounced. Number
of different psychotropic medications used before
quetiapine treatment—a marker for illness severity
in addition to prior mental health charges—seems
unrelated to initial dose, also reﬂecting a weak link
between patient symptomology and dosing. Among
both diagnostic groups, patients prescribed higher
Table 2 Characteristics of patients with schizophrenia or bipolar disorder treated with quetiapine—all patients and stratiﬁed
by lower and higher initial dose*
Patient/treatment characteristics
Schizophrenia Bipolar 
All
Lower 
dose
Higher 
dose All
Lower 
Dose
Higher  
dose
Initial dose, mean (SD) (mg/day) 237 (198) 111 (62) 414 (187) 147 (171) 68 (31) 301 (219)
Age, mean (SD) (year) 40 (14) 40 (15) 40 (13) 35 (15) 35 (16) 35 (15)
Sex, % male 44 42 48 35 34 37
Type of schizophrenia (%)
Paranoid 18 15 22 NA NA NA
Schizoaffective 53 55 50 NA NA NA
Other 29 30 28 NA NA NA
Type of bipolar disorder (%)
Manic NA NA NA 11 10 12
Depressed NA NA NA 15 16 14
Mixed NA NA NA 20 19 21
Unspeciﬁed NA NA NA 54 55 53
Mental health charges during 3 months before quetiapine 
treatment, mean (SD)
$4,714 
(16,300)
$2,886 
(6,975)
$7,294 
(23,704)
$4,256 
(14,687)
$3,545 
(12,749)
$5,636 
(17,788)
Number of different psychotropic therapies during
3 months before quetiapine treatment, mean (SD)
1.3 (1.1) 1.4 (1.1) 1.3 (1.2) 1.4 (1.1) 1.4 (1.1) 1.4 (1.2)
Other health charges during months 2–4 of quetiapine 
treatment, mean (SD)
$1,705 
(4,257)
$1,579 
(3,619)
$1,883 
(5,025)
$2,074 
(5,541)
$2,131 
(5,884)
$1,965 
(4,807)
Switched from prior antipsychotic (%) 44 43 46 31 29 35
Type of health coverage (%)
HMO 54 52 57 45 47 41
POS 9 8 11 18 17 19
PPO 23 25 20 26 25 26
Indemnity 4 4 3 3 3 3
Other 10 11 9 8 8 11
Geographic location (%)
Northeast 14 15 13 15 16 12
Midwest 42 41 45 38 37 39
South 28 32 22 30 30 30
West 16 12 20 17 17 19
Number of treatment episodes 581 340 241 2421 1598 823
*Higher dose is deﬁned as greater than or equal to and lower dose as less than the overall mean dose of 237 mg/day for schizophrenia and 147 mg/day for bipolar
disorder.
HMO, health maintenance organization; NA, not applicable; POS, point of service; PPO, preferred provider organization.
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initial doses of quetiapine were more likely to have
switched from another antipsychotic, supporting the
argument that transitioning is not associated with
lower initial quetiapine doses. Type of coverage and
geographic location show little relationship with
quetiapine dose among bipolar patients. The greater
variation among schizophrenia patients with respect
to geographic location may be attributed to the
smaller sample size. These characteristics were spec-
iﬁed as control variables in the regression models
along with prior mental health charges.
Regression results showing associations between
initial quetiapine dose and subsequent mental
health service use are reported in Table 3. Both
diagnostic groups showed negative associations
between daily dose and mental health charges. For
schizophrenia, the relationship trended toward sta-
tistical signiﬁcance (P = 0.1097), with a decrease of
$1.28 in mental health charges for each additional
milligram of quetiapine. This suggests that each
25 mg/day increase in dose, the standard increment
for quetiapine, would reduce charges by $32 or
2.4% based on overall mean charges of $1341. A
breakdown of the data showed that this decrease
was largely explained by fewer hospitalizations.
Each 1 mg increase in initial quetiapine dose was
associated with relative odds of hospitalization of
0.996 (P = 0.0189). Based on this estimate, a
25 mg/day increase in quetiapine dose yields
relative odds of 0.905 ((0.996)25) [16], which is
equivalent to a 9.5% decrease in the rate of hospi-
talization from the observed rate of 0.041 for all
schizophrenia patients. Quetiapine dose did not
have a statistically signiﬁcant association with out-
patient mental health charges.
Among bipolar patients, a 1-mg increase in ini-
tial quetiapine dose was associated with a $1.31
decrease in subsequent mental health charges
(P = 0.0484). Based on this estimate and mean total
charges of $1781, each 25 mg/day increase in
quetiapine dose is associated with a $33 or 1.6%
decrease in these charges. A breakdown of the data
showed a $0.54 decline in outpatient mental health
charges for each additional milligram of quetiapine
(P = 0.074). Based on this estimate and mean out-
patient charges of $808, each 25 mg/day increase
in quetiapine dose would lower outpatient charges
by $14 or 1.7%. The association between initial
quetiapine dose and subsequent hospitalization was
not statistically signiﬁcant for bipolar patients.
Among the control variables speciﬁed in the
regression models, prior mental health charges were
invariably strong predictors of mental health service
use during quetiapine treatment for both bipolar
and schizophrenia patients. Among schizophrenia
patients, paranoid types had higher levels of mental
health service use than schizoaffective and other
types. Among bipolar patients, mental health serv-
ice use was highest for the mixed type and declined
with patient age. Location in the South or Midwest
was associated with lower mental health charges
than location in the Northeast or West.
The association between initial quetiapine dose
and the likelihood of increasing dose in months 2–
4 of treatment was also statistically evaluated using
a logistic regression model similarly speciﬁed
(Table 4). Examination of the data showed that
53% in the low-dose cohorts of both schizophrenia
and bipolar patients subsequently increased dose,
whereas in the high-dose cohorts 30% and 34%,
Table 3 Estimated effects of increasing initial quetiapine dose on mental health service use of schizophrenia and bipolar
patients
Variable
Type of
model
Parameter estimate 
(impact per quetiapine)
milligram
Impact of 25 mg
increase in
quetiapine dose*
Percent
impact P value
Schizophrenia
Mental health charges in months 2–4 of quetiapine
treatment
OLS –$1.28 –$32 -2.4% 0.1097
Likelihood of inpatient hospital use in months 2–4 of
quetiapine treatment
Logistic 0.996 (odds ratio) 0.905 (odds ratio) -9.5% 0.0189
Outpatient mental health charges in months 2–4 of
quetiapine treatment
OLS $0.13 NA NA 0.7572
Bipolar
Mental health charges in months 2–4 of quetiapine
treatment
OLS –$1.31 –$33 -1.6% 0.0484
Likelihood of inpatient hospital use in months 2–4 of
quetiapine treatment
Logistic 1.00 NA NA 0.9769
Outpatient mental health charges in months 2–4 of
quetiapine treatment
OLS –$0.54 –$14 -1.7% 0.0740
*The standard dosage increment for quetiapine is 25 mg/day.
OLS, ordinary least squares.
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respectively, increased dose. For both schizophrenia
and bipolar patients, the odds of adjusting quetia-
pine dose upward increased by 0.3% for each 1 mg
decrease in initial dose (P < 0.0001). Based on these
estimates, a 25 mg/day decrease in initial daily dose
would increase the likelihood of subsequently rais-
ing quetiapine dose by 7.8%.
Discussion
Historically broad recommendations for quetiapine
dosing may in practice have resulted in prescribed
initial doses that were inadequate to maintain
remission of psychotic symptoms. Evidence of this
possibility was investigated through analysis of
claims data of commercially insured patients with
schizophrenia or bipolar disorder who were treated
with quetiapine monotherapy for at least 4 months.
Although signiﬁcant numbers of patients were pre-
scribed initial quetiapine doses that were well into
and beyond the 150 to 750 mg/day historically rec-
ommended range for schizophrenia [1–5], about
one-third of schizophrenia patients and two-thirds
of bipolar patients received initial doses that were
below the lower bound. Guidelines for bipolar dis-
order had not been established at the time this study
was conducted. In a study of patients with schizo-
phrenia or schizoaffective disorder treated with
quetiapine monotherapy, psychotic symptoms
reemerged for most patients after being stabilized
on an initial average (SD) dose of 261 (65) mg/day,
and doses had to be subsequently increased by an
average of 86.5% to maintain remission [17]. Con-
sequences on mental health resource use of the
observed tendency towards conservative quetiapine
dosing were assessed.
The association between initial quetiapine dose
and subsequent mental health service use in months
2–4 of quetiapine treatment was investigated. Doses
from initial quetiapine prescriptions (month 1 of
treatment) were used to assess dose effects because
doses contemporaneous with mental health service
use may have been a reaction rather than deterrent
to the psychotic symptoms necessitating those serv-
ices. For example, a patient initiated on a low dose
may have experienced a recurrence of symptoms,
triggering both additional mental health care and an
upward adjustment of daily dose. Therefore, the
relationship of interest was between initial quetiap-
ine dose and subsequent mental health service use.
Unadjusted data showed that schizophrenia and
bipolar patients prescribed higher initial quetiapine
doses, where higher was deﬁned as greater than the
mean dose, experienced larger percent reductions in
mental health charges during months 2–4 of quetiap-
ine treatment than those prescribed lower doses.
Regression models adjusting for differences
among patients were used to estimate the relation-
ship between initial quetiapine dose and subsequent
mental health charges. The relationship was nega-
tive for both diagnostic groups, being signiﬁcant for
bipolar disorder (P = 0.0484) and trending toward
signiﬁcance for schizophrenia (P = 0.1097). The
negative relationship implies that higher initial
quetiapine doses result in lower subsequent levels of
mental health service use. A 25 mg/day increase in
initial dose, the standard increment for quetiapine,
was associated with a 2.4% reduction in mental
health charges for schizophrenia and a 1.6% reduc-
tion for bipolar disorder. Dose effects on mental
health charges were estimated as a proxy for dose
effects on patient stability and not as an indicator of
any cost saving effect of quetiapine.
That quetiapine dosing practices are too conserv-
ative was also supported by ﬁndings relating to the
association between initial quetiapine dose and sub-
sequent adjustments to dose. If initial quetiapine
doses were set entirely according to the needs of
each patient, then the likelihood of subsequently
raising the dose should be unrelated to the initial
dose. This was not found to be the case. For both
schizophrenia and bipolar disorder, patients pre-
scribed lower initial doses were more likely to have
subsequent upward adjustments (P < 0.0001).
Table 4 Relationship between quetiapine initial daily dose and odds of increasing subsequent daily dose
Group
Type of
model
Effect on odds of increasing 
quetiapine dose in months 2–4
of treatment per 1 mg 
decrease in initial daily dose
Effect on odds of increasing 
quetiapine dose in months 2–4
of treatment per 25 mg/day 
decrease in initial daily dose* P-value
Schizophrenia Logistic 1.003 1.078 <0.0001
Number increasing dose: 253
Number not increasing dose: 328
Bipolar disorder Logistic 1.003 1.078 <0.0001
Number increasing dose: 1123
Number not increasing dose: 1298
*The standard dosage increment for quetiapine is 25 mg/day.
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Our database ﬁndings are consistent with clinical
ﬁndings suggesting that higher quetiapine doses
would be more effective. Doses in excess of 250 mg/
day, [10] 400 mg/day, [8] 600 mg/day [11], and,
for treatment-refractory schizophrenia patients,
1200 mg/day [12] are supported by clinical ﬁnd-
ings. Higher doses of quetiapine are further sup-
ported by evidence that side effects are mild to
manageable and are generally well tolerated even in
the very high dose range [12,18]. Consistent with
these clinical ﬁndings, the recommended dose range
for quetiapine in the treatment of schizophrenia has
been recently increased to 300 to 800 mg/day from
the historical 150 to 750 mg/day [19].
A limitation of this study is that it does not and
cannot, given the nature of the data, provide further
guidance as to which quetiapine dose levels would
be optimal. The commercially insured patients who
were the subjects of this study are generally less
severely ill than disabled schizophrenia and bipolar
patients, who tend to be institutionalized for long
periods and are typically represented in clinical tri-
als. Therefore, the dose levels suggested in the
above clinical studies may not apply to the typical
commercially insured patient. This study shows
only that quetiapine initiation schedules may have
been too conservative in real practice. Another lim-
itation to bear in mind is the possibility that, for
patients who switched to quetiapine from another
antipsychotic using a “cross-tapering strategy,”
inaccuracies in measuring initial quetiapine dose
may have occurred. For these patients, initial
quetiapine doses would have been artiﬁcially low
and may have affected the above estimates to some
unknown degree. Unfortunately, given the inherent
limitations of claims data, these patients could not
be identiﬁed.
Although methods used in this study are for the
most part common to health-care analyses, there
are some deviations from usual practice that have
been defended in another publication [20]. Of par-
ticular note is the decision not to convert mental
health charges to logarithmic form before estimat-
ing the regression models. Although this common
practice adjusts for the highly skewed nature of
health-care data, it can distort between-group com-
parisons [21] Log transformation condenses the tail
(high end) of the health charge distribution, in effect
making differences here relatively much smaller. If
higher quetiapine doses were more effective in
reducing the higher mental health service use of
more seriously ill patients, then this effect would be
largely negated with log transformation. Tests of the
data showed this to be the case. For example,
regression models for schizophrenia and bipolar
mental health charges were reestimated including a
term reﬂecting the interaction between initial
quetiapine dose and prior mental health charges
(the indicator of illness severity strongly associated
with mental health service charges during treat-
ment). In both models this term was negative and
signiﬁcant (P < 0.010) suggesting that the effects of
higher quetiapine dose are concentrated among the
most seriously ill patients. The “bootstrap” method
has been recommended as an alternative to log
transformation, but the accuracy of this method is
assured only with very large samples [22]. Nonpar-
ametric tests of the data were also judged to be
unsuitable for assessing differences between the
groups.
A more comprehensive study might have
observed patients over a longer period than the four
months used here. Such a study may be in the form
of a time-series cross-sectional analysis with mental
health services in each period being regressed on the
lagged value of quetiapine dose. In this way, it could
be determined if a more aggressive quetiapine
dosing strategy sustained over long periods would
result in better health outcomes. To avoid serious
bias, however, modeling would have to address
treatment discontinuations which, among the less
seriously ill commercially insured, do not necessar-
ily reﬂect treatment failure and are difﬁcult to inter-
pret in claims data.
Conclusions
Findings from this study suggest that, in the treat-
ment of schizophrenia and bipolar disorder, more
aggressive dosing schedules for quetiapine than
have been used in practice may be more effective, as
reﬂected in lower levels of other mental health serv-
ice use. Too conservative dosing may have been
encouraged by historical guidelines that were too
broad.
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